Results 61 to 70 of about 41,661 (291)

Clinical significance of prostate volume and testosterone reduction on lower urinary tract symptoms in patients with prostate cancer undergoing androgen deprivation therapy

Scientific Reports, 2022
To investigate the effect of both prostate volume and serum testosterone changes on lower urinary tract symptoms in patients with prostate cancer undergoing androgen deprivation therapy.
Woo Jin Bang, Hwanik Kim, Cheol Young Oh, Jung Ki Jo, Jin Seon Cho, Myungsun Shim   +5 more
doaj   +1 more source

No increased risk of coronary heart disease for patients receiving androgen deprivation therapy for prostate cancer in Chinese/Taiwanese men

, 2017
The relationship between androgen deprivation therapy (ADT) and coronary heart disease (CHD) remains controversial. Furthermore, the majority of such studies focused on Caucasian populations, and there is still a paucity of studies among Asian ...
Wang, L. H.;Liu, C. K.;Chen, C. H.;Kao, L. T.;Lin, H. C.;Huang, C. Y., 黃昭淵   +1 more
core   +1 more source

Temporal trends in cardiovascular burden among patients with prostate cancer receiving androgen deprivation therapy: a population-based cohort study [PDF]

, 2023
Background Although androgen deprivation therapy (ADT) is associated with cardiovascular risks, the extent and temporal trends of cardiovascular burden amongst patients with prostate cancer receiving ADT are unclear.
Yan Hiu Athena Lee, Kang Liu, Jeremy Man Ho Hui, Chi Fai Ng, Gary Tse, Danish Iltaf Satti, Kenrick Ng, Jeffrey Shi Kai Chan, Edward Christopher Dee   +8 more
core   +1 more source

NQO1‐Mediated Anoikis Resistance and Immune Evasion Define a High‐Risk Multi‐Omic Subtype for Precision Management of T1 High‐Grade Bladder Cancer

Advanced Science, EarlyView.
Multi‐omic profiling of T1 high‐grade bladder cancer identifies a high‐risk subtype (T1HG1) driven by NQO1, which couples anoikis resistance with immune evasion. NQO1 orchestrates macrophage–T cell crosstalk suppression via CXCL9 modulation. Pharmacological NQO1 inhibition with skullcapflavone II enhances cisplatin efficacy, representing a promising ...
Bin Guo, Chunru Xu, Shufan Fu, Qiang Cheng, Juan Li, Linkuo Shang, Gaojie Li, Yang Yang, Ying Wang, Yanqing Gong, Shengwei Xiong, Jian Fan, Changwei Yuan, Mei Zhang, Yifan Zuo, Elena Papaleo, Yue Shi, Yuan Liang, Xuesong Li, Hongzhao Li, Weimin Ci   +20 more
wiley   +1 more source

Riscos cardiovasculares do bloqueio androgênico Riesgos cardiovasculares del bloqueo androgénico Cardiovascular risks of androgen deprivation therapy

Arquivos Brasileiros de Cardiologia, 2010
O adenocarcinoma de próstata é o câncer mais comum no sexo masculino após o câncer de pele. Entre as várias formas de tratamento do câncer de próstata, a terapia de bloqueio androgênico é uma modalidade consagrada nos pacientes com doença metastática ou ...
Adriano Freitas Ribeiro, César Camara, Carlos Alexandre Segre, Miguel Srougi, Carlos V. Serrano Jr   +4 more
doaj   +1 more source

Successive xanthogranulomatous prostatitis after complete remission of metastatic prostate adenocarcinoma: An extremely rare case report with review of literatures

Urology Case Reports, 2020
Xanthogranulomatous prostatitis is a rare occasion that mimics the prostate cancer in every aspect of clinical diagnosis. These two occasions require totally diverse therapeutics principles. Thus, emphasis should be exerted to distinguish them.
Che-Hsueh Yang, Chin-Heng Lu, Li-Hua Huang, Yen-Chuan Ou, Chao-Yu Hsu, Min-Che Tung   +5 more
doaj   +1 more source

Effects of androgen deprivation therapy on telomere length [PDF]

Clinical Endocrinology, 2017
SummaryObjectiveRecent evidence suggests that androgens either directly or via aromatisation to oestradiol may regulate telomere length, hence providing a mechanism whereby reproductive steroids are linked to biological ageing in men. Using men with prostate cancer initiating androgen deprivation therapy (ADT), we tested the hypothesis that severe sex ...
Ada S. Cheung, Bu B. Yeap, Rudolf Hoermann, Jennie Hui, John P. Beilby, Mathis Grossmann   +5 more
openaire   +3 more sources

Re: Final Report of the Intergroup Randomized Study of Combined AndrogenDeprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer

, 2015
No certain treatment recommendations were given for locally advanced or high-risk prostate cancer in the European Association of Urology (EAU) guidelines (1).
Wendy R. Parulekar, Malcolm D. Mason, Matthew R. Sydes   +2 more
core   +1 more source

ANXA2‐mediated Phagocytosis Generates AR+ Macrophages to Confer Enzalutamide Resistance in Prostate Cancer

Advanced Science, EarlyView.
A novel resistance mechanism is mediated through phagocytosis of cancer cells by AR+ TAMs. This process, dependent on ANXA2, enables macrophages to acquire AR protein from engulfed tumor cells. The internalized AR translocates into the macrophage nucleus, where it binds directly to the IL‐6 promoter, augmenting IL‐6 transcription and secretion ...
Yong Luo, Tianlong Luo, Lingfeng Li, Qi Sun, Dongquan Li, Shanhe Huang, Zonglin Li, Weilong Lin, Yuan Ou, Tao Du, Shengmeng Peng, Kewei Xu, Bisheng Cheng, Hai Huang   +13 more
wiley   +1 more source

A randomized controlled trial on the effectiveness of strength training on clinical and muscle cellular outcomes in patients with prostate cancer during androgen deprivation therapy: rationale and design

BMC Cancer, 2012
Background Studies indicate that strength training has beneficial effects on clinical health outcomes in prostate cancer patients during androgen deprivation therapy.
Thorsen Lene, Nilsen Tormod S, Raastad Truls, Courneya Kerry S, Skovlund Eva, Fosså Sophie D   +5 more
doaj   +1 more source